Interestingly, a previous study had reported that microRNA‐3609 could attenuate the expression of EPAS1 and sensitize HCC cells to sorafenib treatment [71]; that study was the first to reveal the potential role of EPAS1 in HCC treatment. Here, EPAS1 is linked to hepatocellular carcinoma.